Now Available: Fetal RhD NIPT

Plan ahead for your Rh negative pregnant patients

Vivienne Souter
MD MPH FACMG FACOG
Medical Director, Women's Health

The evolution of NIPT: what comes next

Fetal RhD NIPT to inform management of Rh negative pregnant patients

In this webinar Dr Vivienne Souter MD MPH will discuss RhD and its role in pregnancy, and review data from a large clinical validation study of Fetal RhD NIPT.

Watch Now

Get highly accurate fetal RhD NIPT

Natera’s Fetal RhD NIPT is backed by the largest fetal RhD NIPT clinical validation study with confirmed outcomes in the US.¹ Add Fetal RhD to Panorama™ NIPT for Rh negative patients who are alloimmunized or at risk for alloimmunization.

655

Rh- patients

Sensitivity: 100%, 95% CI^* (98.9-100%)

Fetal Rh+

n = 356/356

Specificity: 99.3%, 95% CI (97.6-99.8%)

Fetal Rh-

n = 295/297

In the validation study, fetal RhD status was reported for 99.7% of patients (n=653/655)

^{*CI=confidence interval. In clinical use false negatives and false positives are possible and may occur.}

Perspectives on Natera’s Fetal RhD NIPT

Hear a practicing OB/GYN’s thoughts on the new Fetal RhD NIPT validation and its clinical utility

Clinical Validation of a SNP-based Prenatal Cell-free DNA Screening Test for Fetal RHD Status in a Large US Cohort

Watch Jeffrey T. Meltzer, MD, MBA, Senior Medical Director, review the clinical validation study for Natera’s Fetal RhD NIPT that was presented as a late-breaking abstract at the 2024 ACOG Annual Clinical and Scientific Meeting.

Inform decisions about RhD immune globulin

“…the use of NIPT to prioritize use of RhIg and conserve RhIg supply is a reasonable consideration in the practice setting that is experiencing RhIg shortages. Noninvasive fetal red blood cell antigen genotyping utilizing cell-free DNA (cfDNA) isolated from maternal plasma has demonstrated high sensitivity and specificity for detection of fetal Rh(D) antigen status”

ACOG Rho(D) Immune Globulin Shortages Practice Advisory, updated April 2024²

Order with ease

Provide comprehensive prenatal screening with the #1 ordered NIPT and carrier screen⁵

Order Fetal RhD NIPT on the same form with the Panorama™ Horizon™ Combo Kit
No additional sample required
Receive results on the Panorama™ report

Robust support for you and your patients

Clear, actionable reports
Broad in-network coverage and financial access programs for patients who qualify. Learn more
Complimentary pre- and post-test genetic information sessions with Natera’s board-certified genetic counselors
NEVA, Natera’s Educational Virtual Assistant, which provides 24-7 access to results in English and Spanish. Learn more.

PAN_WEB_Clinician_Tab_Module3_20231019_NAT-1043

Incorporate Fetal RhD NIPT for your pregnant patients

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Meltzer et al., Validation of a SNP-based Prenatal cell-free DNA screening for Fetal RhD Status in a Large US Cohort, ACOG Annual Clinical and Scientific Meeting, May 2024, San Francisco, CA.

²ACOG Rho(D) Immune Globulin Shortages Practice Advisory. March 2024, updated April 2024

Fetal RhD NIPT provides a genotyping test result that determines the RhD gene sequence associated with fetal RhD status for pregnant RHD- (negative) people. Fetal RhD genotype does not always correlate with the phenotype. Panorama™ and Fetal RhD NIPT have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). CAP accredited, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved.